Genelabs Technologies, Inc.

The United States of America As Represented by the Department of Health

Michael A Purdy

Gregory R Reyes

Albert W Tam

Daniel W Bradley

Krzysztof Z Krawczynski

Jr-Shin Twu

Patrice O Yarbough

Patrice D Yarbough

Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reasing frames of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.

Hepatitis E virus vaccine and method

An antigen composition hepatitis E virus (HEV) infection are disclosed. The antigen composition includes peptides corresponding to carboxyl terminal end regions of the second and third open reading frames of the HEV genome.

Hepatitis E virus ORF Z peptides

Antigen and antibody vaccine composition effective in preventing hepatitis E virus (HEV) infection are disclosed. The antigen composition includes a peptide corresponding to a carboxyl terminal end region of the capsid protein encoded by the second open reading frame 2 of the HEV genome. The composition is effective in preventing HEV infection after vaccination. The antibody composition contains an antibody effective to block HEV infection of human primary hepatocytes in culture.

Growing community of inventors

Atlanta, GA, United States of America

Michael A Purdy